On March 29, the general office of the Shanghai Municipal People’s government issued several policies and measures for Shanghai to fight the epidemic and help enterprises promote development (hereinafter referred to as “several policies and measures”), and issued 21 measures to fight the epidemic and help enterprises promote development and reduce the impact of the epidemic on economic and social development. Several policies and measures proposed to support the R & D and industrialization of covid-19 virus prevention and control innovative products. Support covid-19 virus vaccine, rapid detection reagent and specific drugs to accelerate scientific and technological R & D and industrialization.
In the face of repeated epidemics, listed companies took positive action. More than two of the listed companies on the science and innovation board have become biomedical enterprises. Taking advantage of the capital market, these companies actively invest in the R & D and production of innovative drugs, vaccine R & D and vaccination, as well as the development of covid-19 testing reagent, so as to strongly support the “anti epidemic” outside China and highlight the background of “hard technology”.
accelerate the research and development of innovative drugs and vaccines
contribute to the global “anti epidemic”
to cope with the epidemic situation, more than 10 pharmaceutical companies on the scientific innovation board have successively invested in the R & D and production of relevant specific drugs and APIs to help the global “fight against the epidemic”
as a pioneer of local innovative pharmaceutical companies, Shanghai Junshi Biosciences Co.Ltd(688180) was invested in the research and development work of “anti epidemic” drugs at the initial stage of the outbreak. has now developed a R & D pipeline consisting of a number of COVID-19 neutralizing antibody drugs and small molecule oral drugs. The company’s covid-19 virus neutralizing antibody js016 was authorized by Eli Lilly in 2020. At present, it has been authorized for emergency use in 15 countries and regions. The COVID-19 oral drug VV116 developed by the company has been approved for moderate to severe New Coronavirus pneumonia in Uzbekistan. It has also conducted clinical trials in many countries around the world and has completed the first case of III in the clinical period.
“Recently, vv116, the company’s first oral anti covid-19 virus drug, released three phase I clinical data, showing satisfactory safety, tolerance and pharmacokinetic properties, adding confidence to the ‘anti epidemic’.” Shanghai Junshi Biosciences Co.Ltd(688180) relevant people told the reporter of Securities Daily that based on the above positive results, the company has carried out two phase III clinical studies for mild, moderate and severe cases. In addition, the company actively donated money and materials to areas with serious epidemic situation, and four Shanghai laboratory employees volunteered to go to the front-line “anti epidemic” to help the nucleic acid detection of covid-19 virus in Shanghai.
as a non-profit enterprise without product approval at the time of listing, Sinocelltech Group Limited(688520) actively invested in the research and development of covid-19 virus neutralizing antibody after listing , with the help of the capital market, it plans to raise 2.24 billion yuan through refinancing, of which 457 million yuan will be directly used for the research and development of covid-19 virus neutralizing antibody. In addition, the company is also developing the recombinant covid-19 virus alpha + beta mutant s trimer protein vaccine at the same time. The existing research shows that the product can stimulate stronger and broader spectrum neutralizing antibody titer of the mutant, which can more effectively resist the risk of infection of the mutant.
Under the background of repeated epidemic and frequent occurrence of mutated strains, the research, development and vaccination of relevant vaccines have played a key role in combating the epidemic and blocking the transmission.
innovative vaccine leader Cansino Biologics Inc(688185) is also working hard to develop and produce vaccine. The recombinant New Coronavirus vaccine (adenovirus type 5), jointly developed by the company and the Institute of biotechnology, has been listed in several countries and is approved by many countries such as China, Malaysia and Indonesia as a strengthening needle. It became the first adenovirus vector covid-19 vaccine approved for sequential booster immunization in China. At present, the clinical trials of the vaccine have been carried out in more than 70 clinical research centers, and the vaccination of more than 40000 subjects has been completed. The analysis results of phase III clinical trials of global multicenter have been successfully published in the lancet. In addition, Cansino Biologics Inc(688185) is further developing inhaled covid-19 vaccine and actively distributing mRNA covid-19 vaccine.
nucleic acid detection is as fast as “minute level”
control the first level of epidemic prevention and control
As the first pass of epidemic prevention and control, improving the detection efficiency of covid-19 virus is conducive to the “early detection” of the virus.
many companies related to in vitro diagnosis of scientific innovation board responded quickly in epidemic prevention and control, developed covid-19 nucleic acid detection reagent, developed a series of scientific and technological “anti epidemic” products such as rapid nucleic acid detection equipment and respiratory disease joint detection reagent at the first time , and actively sent personnel to test services to build a “anti epidemic” defense line.
aiming at the pain points and difficulties of nucleic acid detection, Sansure Biotech Inc(688289) developed a rapid nucleic acid detection system , broke the bottleneck of application scenarios such as professional laboratories, and promoted the nucleic acid detection from the previous “hour level” to “minute level”. The results can be obtained in 15 to 45 minutes, and the sensitivity is higher. The system has passed the registration certification of the State Food and Drug Administration and the EU CE certification.
Shanghai Zj Bio-Tech Co.Ltd(688317) , Jiangsu Bioperfectus Technologies Co.Ltd(688399) and other companies have also developed and issued mobile nucleic acid detection vehicles , highly integrated biosafety assurance system, equipped with automatic nucleic acid detection equipment and laboratory intelligent management system produced by the company, so as to realize the integration of the whole process from sample collection, automatic sample pretreatment, nucleic acid extraction, nucleic acid detection to final report issuance, integrating the traditional The immovable PCR laboratory becomes a movable nucleic acid detection base.
at present, the self-produced antigen reagents of five companies listed on the science and innovation board have been approved for listing The antigen self-test reagents of Nanjing Vazyme Biotech Co.Ltd(688105) and Hangzhou Alltest Biotech Co.Ltd(688606) can detect N protein and S protein at the same time, which can maximize the sensitivity and detection rate of the reagent on the premise of ensuring the detection specificity. In addition, the antigen reagents of Asahi biology, Hangzhou Biotest Biotech Co.Ltd(688767) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Beijing Hotgen Biotech Co.Ltd(688068) and other companies are exported to America, Europe and Australia
as the leader of IVD in vitro diagnosis in China, Zhejiang Orient Gene Biotech Co.Ltd(688298) covid-19 antigen detection reagent took the lead in comprehensively promoting the use of in the European market as early as July 2020. Later, it was admitted by the U.S. FDA at the end of December 2021 and recently allowed to enter the Japanese market.
Zhejiang Orient Gene Biotech Co.Ltd(688298) relevant people told the reporter of Securities Daily that by the end of 2021, with industry-leading technical indicators and stable and reliable quality assurance, the company’s covid-19 antigen detection reagent had actually detected more than 1 billion people in the European and American markets, which is one of the few products that have been continuously applied on a large scale in the European and American markets. In 2021, the company’s export revenue of covid-19 antigen detection reagents accounted for about 15% of the total export revenue of covid-19 detection reagents (including nucleic acids) in China, which was further higher than that in 2020. Last year, the company’s net profit was 4.8 billion yuan, mainly due to the application of covid-19 antigen detection reagent in the European market.
\u3000\u3000 “Based on the company’s large-scale clinical and practical applications in Europe and the United States and other developed countries, the overall production capacity has significant advantages, with a daily output of 18 million people. On March 15, the company’s covid-19 antigen detection reagent successfully obtained the registration and certification of Chinese products. Subsequently, the company helped China’s national defense epidemic for the first time, and has donated millions of reagents. At the same time, the company immediately started supporting China’s production capacity, tried its best to overcome the production capacity bottleneck and meet the needs of China to the greatest extent The need for epidemic prevention and control in China. Recently, tens of millions of covid-19 antigen detection reagents have been sent to Shanghai and other places. ” Zhejiang Orient Gene Biotech Co.Ltd(688298) the above person further introduced.
